Dual variable domain immunoglobulins and uses thereof

TL;DR: In this paper, the authors provide compositions and methods for treating diseases associated with expression of CD19, including methods of administering a genetically modified T cell expressing a chimeric antigen receptor (CAR) that comprises a CD19 binding domain.

TL;DR: In this paper, the diabody molecules of the present invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on different or differing antigens.

TL;DR: In this article, the anti-PD-1 antibody molecules can be used to treat, prevent and diagnose cancerous or infectious conditions and disorders, and they can be found to specifically bind to PD-1.

TL;DR: The results of antibody binding studies indicate that the epitope is closely linked to the EGF binding active site, and is common to both high- and low-affinity EGF-receptors.

TL;DR: It is suggested that both positive (IL-1) and negative (PGE2) signals may control collagen synthesis at the transcriptional level resulting in modulation of matrix turnover in cartilage, synovium, and skin.

TL;DR: In this article, the authors describe the use of antibody compositions and their use in the treatment of inflammatory disorders. But they do not describe their methods for treating inflammatory disorders, only their compositions and methods for synthesizing antibody compositions.

TL;DR: In this article, a method for producing mixtures of antibodies from a single host cell clone is described, where a nucleic acid sequence encoding a light chain and nucleic acids sequences encoding different heavy chains are expressed in a recombinant host cell.